GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

NNC0519-0130

Company
Novo Nordisk A/S
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for NNC0519-0130 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06717698

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

    Not yet reported Novo Nordisk A/S 465 participants Est. completion 2026-09-17 147 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Completed NCT NCT05363774

    A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

    Not yet reported Novo Nordisk A/S 161 participants Est. completion 2024-04-02 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05870670

    A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

    Not yet reported Novo Nordisk A/S 22 participants Est. completion 2023-10-16 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06326047

    A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 299 participants Est. completion 2025-10-13 110 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06326060

    A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

    Not yet reported Novo Nordisk A/S 354 participants Est. completion 2025-05-01 70 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06370819

    A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

    Not yet reported Novo Nordisk A/S 36 participants Est. completion 2024-11-27 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06513104

    A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause

    Not yet reported Novo Nordisk A/S 47 participants Est. completion 2025-09-30 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06567041

    A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes

    Not yet reported Novo Nordisk A/S 82 participants Est. completion 2025-12-10 1 site Stand-alone
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06642571

    A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine

    Not yet reported Novo Nordisk A/S 46 participants Est. completion 2025-05-31 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06718998

    A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity

    Not yet reported Novo Nordisk A/S 134 participants Est. completion 2026-01-12 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT07004322

    A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight

    Not yet reported Novo Nordisk A/S 20 participants Est. completion 2026-01-28 1 site Stand-alone
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.